Tvardi Therapeutics (TVRD) Share-based Compensation: 2012-2024
Historic Share-based Compensation for Tvardi Therapeutics (TVRD) over the last 13 years, with Dec 2024 value amounting to $8.9 million.
- Tvardi Therapeutics' Share-based Compensation rose 118.34% to $1.8 million in Q4 2017 from the same period last year, while for Dec 2017 it was $6.3 million, marking a year-over-year increase of 126.07%. This contributed to the annual value of $8.9 million for FY2024, which is 34.97% down from last year.
- Latest data reveals that Tvardi Therapeutics reported Share-based Compensation of $8.9 million as of FY2024, which was down 34.97% from $13.7 million recorded in FY2023.
- In the past 5 years, Tvardi Therapeutics' Share-based Compensation ranged from a high of $20.8 million in FY2021 and a low of $8.9 million during FY2024.
- Moreover, its 3-year median value for Share-based Compensation was $13.7 million (2023), whereas its average is $13.5 million.
- As far as peak fluctuations go, Tvardi Therapeutics' Share-based Compensation spiked by 40.11% in 2021, and later tumbled by 34.97% in 2024.
- Tvardi Therapeutics' Share-based Compensation (Yearly) stood at $14.8 million in 2020, then soared by 40.11% to $20.8 million in 2021, then fell by 14.68% to $17.7 million in 2022, then decreased by 22.58% to $13.7 million in 2023, then slumped by 34.97% to $8.9 million in 2024.